Valeant Pharmaceuticals International Inc. (VRX)

17.47
NYSE : Health Technology
Prev Close 17.47
Day Low/High 0.00 / 0.00
52 Wk Low/High 8.50 / 24.43
Avg Volume 10.23M
Exchange NYSE
Shares Outstanding 348.84M
Market Cap 6.12B
EPS 6.90
P/E Ratio 2.57
Div & Yield N.A. (N.A)

Latest News

American Airlines, ABB Ltd., Salesforce.com: 'Mad Money' Lightning Round

American Airlines, ABB Ltd., Salesforce.com: 'Mad Money' Lightning Round

Jim Cramer focuses on American Airlines, Salesforce.com, Realty Income, Proctor & Gamble, United Bankshares, iRobot, Dominion Energy.

Rally Climbs on Earnings: Cramer's 'Mad Money' Recap (Thursday 4/12/18)

Rally Climbs on Earnings: Cramer's 'Mad Money' Recap (Thursday 4/12/18)

Good earnings reports, cooling oil, and tech leadership all contributed to Thursday's gains, says Jim Cramer. Along with no explosive presidential tweets.

Ready for Tesla's New Model Y? Here's When to Expect It

Ready for Tesla's New Model Y? Here's When to Expect It

Tesla's Model Y could begin production in November 2019, but don't get your hopes up.

Getting Ready for Biotech Earnings

Getting Ready for Biotech Earnings

Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.

Closing Bell: LIVE MARKETS BLOG

Closing Bell: LIVE MARKETS BLOG

Markets closed near session highs Thursday.

Bill Ackman Needs a Big Win at ADP or Another Target to Stop the Bleeding

Bill Ackman Needs a Big Win at ADP or Another Target to Stop the Bleeding

The embattled activist is reportedly experiencing significant redemptions as investors seek to flee his fund. A campaign at the payroll processor in 2018 is a real possibility as Ackman has $500 million committed to a co-investment targeting the company

Alkermes Surprised, Angered by FDA Rejection of Antidepressant

Alkermes Surprised, Angered by FDA Rejection of Antidepressant

Alkermes says the rejection of antidepressant drug ALKS 5461 is a head-scratcher, and it's calling for a prompt meeting with the regulator to get to the bottom of the decision.

AbbVie Dip Presents Rare Buying Opportunity; Activist Steps Up at SuperValu

AbbVie Dip Presents Rare Buying Opportunity; Activist Steps Up at SuperValu

Here's what you need to know now for Thursday, March 22.

Valeant Pharmaceuticals Is Back to Playing Defense

Valeant Pharmaceuticals Is Back to Playing Defense

What do the charts and indicators look like today? Let's check.

Could Valeant's Stock Blow Up by 40%?

Could Valeant's Stock Blow Up by 40%?

There are still skeptics when it comes to Valeant Pharmaceuticals -- and for good reason.

Dow Dives 380 Points, Posting Its First Losing February Since 2009

Dow Dives 380 Points, Posting Its First Losing February Since 2009

Stocks dropped on Wednesday as global investors parse potentially hawkish comments from Federal Reserve Chairman Jerome Powell and fourth-quarter GDP meets expectations.

Super Bowl of Earnings: Cramer's 'Mad Money' Recap (Friday 1/26/18)

Super Bowl of Earnings: Cramer's 'Mad Money' Recap (Friday 1/26/18)

Politics, Davos, news -- none of it matters as much as earnings. Here's Jim Cramer's game plan for next week.

Valeant CEO: Drugmaker Knee-Deep in 'Turnaround Effort of a Lifetime'

Valeant CEO: Drugmaker Knee-Deep in 'Turnaround Effort of a Lifetime'

With the stock of the drugmaker hovering around $23 a share and its reputation bloodied, CEO Joe Papa tried to explain his company's comeback efforts to investors.

5 Things We Learned About Activist Investing in 2017

5 Things We Learned About Activist Investing in 2017

Insurgent managers had another busy year. But behind the numbers there were some fascinating trends and surprising tactics. Here's our review of the year that was.

Valeant Pharmaceuticals Stock Still a Dog?

Valeant Pharmaceuticals Stock Still a Dog?

The drugmaker's stock has rallied about $10 in just a few weeks, so a period of consolidation or sideways movement would be expected.

No Two Stocks Are the Same: Cramer's 'Mad Money' Recap (Tuesday 12/12/17)

No Two Stocks Are the Same: Cramer's 'Mad Money' Recap (Tuesday 12/12/17)

In markets like this, Jim Cramer says, tune out the noise and look at individual stocks like Disney, Boeing and Caterpillar.

Cramer: These CEOs Are Creating Value

Cramer: These CEOs Are Creating Value

Not all stocks are created equal and it's the CEOs who make the difference.

Jim Cramer: Why the Stock Market Isn't Falling

Jim Cramer: Why the Stock Market Isn't Falling

There are plenty of reasons why the stock market isn't falling, from defense and aerospace, to booming energy, to reduced regulation.

Biotech Stocks to Watch: Part 1

Biotech Stocks to Watch: Part 1

Upcoming catalysts will redefine the biotech market -- and here are 3 names that will feel the impact.

Is Valeant Pharmaceuticals Coming Back From the Dead?

Is Valeant Pharmaceuticals Coming Back From the Dead?

The stock is performing better than it has in a long time.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMZN, CKH, GDDY, PRSC, QGEN, SHLM, VRX Downgrades: BRG, CZWI, FBP, HAIN, LNCE, PIH, TAIT, TPR, TTWO Initiations: ASIX, CWH Read on to get TheStreet Quant Ratings' detailed report:

Valeant's Explosive Gains Make the Stock Look Buyable Again

Valeant's Explosive Gains Make the Stock Look Buyable Again

Valeant has long been a stock that nobody wanted to touch -- but drama-free earnings and a bullish breakout move are actually making this stock look buyable in the final stretch of 2017.

Ackman Vows to Return to ADP; Valeant Rises After Asset Sale -- ICYMI

Ackman Vows to Return to ADP; Valeant Rises After Asset Sale -- ICYMI

Here's what you need to know now for Tuesday, Nov. 7.

Bill Ackman Overwhelmingly Loses ADP Battle in Latest Blow to Activist Investor

Bill Ackman Overwhelmingly Loses ADP Battle in Latest Blow to Activist Investor

The insurgent hedge fund manager, who suggested he may be back in 2018 with another boardroom battle, fails in his effort to elect three dissident directors to the board of the payroll processor.

General Electric, Toyota, Snap - 5 Things You Must Know Before the Market Opens

General Electric, Toyota, Snap - 5 Things You Must Know Before the Market Opens

U.S. stock futures suggest Wall Street will open mixed on Tuesday, after the benchmark indexes rallied to fresh records during the previous trading session.

TheStreet Quant Rating: C (Hold)